AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Marketbeat

Published November 4, 2026

Compass Pathways (NASDAQ: CMPS) Price Target Cut to $10.00 by Analysts at Wells Fargo ...

Read the full story at Marketbeat

Institutional Trading of Compass Pathways. Magic Mushrooms , Hard Cash: Compass Pathways' Trial Win, Fast Raise ... psilocybin administered with.

Post on X

Share this story

Surfaced by this Google Alert

Magic mushrooms